Prior to the introduction of innovative targeted therapies, traditional treatments such as EGFR-TKIs, ICIs, and chemotherapy were the primary options for later-line therapy in patients with ex20ins NSCLC (Low et al., 2023). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.